EU Approves Frontline Ceritinib for ALK+ NSCLC

June 29, 2017 – The European Union (EU) has approved the use of ceritinib for the first-line treatment of patients with ALK-positive advanced non­small cell lung cancer (NSCLC). Novartis, the manufacturer of the selective ALK-inhibitor, announced the approval in a press release. Ceritinib will be available for patients in all 28 EU member states plus Iceland, Lichtenstein, and Norway. The approval is based on data from the open-label phase III ASCEND-4 trial, in which … (leggi tutto)